AI Drug Discovery for Pharma and Biotech

Drug discovery

411

papers

On emerging therapies

Overview

Chronic mucocutaneous candidiasis (CMC) is a rare primary immunodeficiency characterized by persistent Candida albicans infections of the skin, nails, and mucous membranes. It arises from genetic defects (e.g., STAT1 GOF or AIRE mutations) impairing IL-17-mediated immunity, often presenting in childhood. Associated with autoimmune polyendocrinopathies, thymoma, or hyper-IgE syndrome, CMC necessitates lifelong antifungal therapy and carries risks of resistance, systemic complications, and malignancy [1][2][6].

Key Clinical Insights

Population

Primarily affects children <3 years, with adult-onset cases linked to thymoma or autoimmune disorders. Genetic variants (STAT1, AIRE) and syndromes (APECED, HIES) are major contributors [1][4][6].

Burden

High morbidity from disfiguring infections, recurrent hospitalizations, and increased mortality due to sepsis, pneumonia, or malignancies. Resistance develops in ~39% of long-term antifungal users, complicating care [3][4][14].

Therapies

  • Antifungals: Azoles (fluconazole, posaconazole) as first-line; echinocandins or amphotericin B for resistant cases [3][8][10].

  • Immunomodulation: JAK inhibitors (e.g., ruxolitinib) to restore Th17 function, GM-CSF therapy, and HSCT in severe cases [3][9][18].

  • Supportive Care: Management of endocrine/autoimmune comorbidities and antifungal resistance monitoring [3][14].

Categories: rare genetic diseases, rare immunological diseases, rare skin diseases

Research Papers

411 drug discovery papers about Chronic mucocutaneous candidiasis. Recent publications:

411 drug discovery papers about Chronic mucocutaneous candidiasis. Recent publications:

categories:

Small molecules

cell therapies
2025-11-28 | The T385M STAT1 gain-of-function mutation confers the most severe disease outcomes

Background Gain-of-function (GOF) mutations in STAT1 cause a combined immunodeficiency characterized by chronic mucocutaneous candidiasis (CMC), recurrent infections, and autoimmunity. Mutations in the DNA-binding domain (DBD) have previously been associated with poor outcomes, but the contributions of specific variants to clinical phenotype remain unexplored. Methods We performed a systematic literature review to identify patients with confirmed STAT1 GOF mutations, integrating new cases with a previously reported international cohort. Clinical and genetic data were analyzed at both domain and mutation level to define genotype-phenotype correlations. Results A total of 533 unique patients from 36 countries were identified, harboring 135 distinct mutations. As previously reported, DBD mutations were associated with increased risk of systemic infections, bronchiectasis, autoimmunity, and reduced survival. However, mutation-level stratification revealed that the T385M variant accounted for much of this effect. Compared with both other DBD mutations and mutations elsewhere in STAT1 , T385M conferred significantly higher rates of infection, bronchiectasis, autoimmunity, and premature death (p &lt; 0.001). Conversely, certain coiled-coil (CC) domain mutations, such as R274Q, were associated with milder disease and improved survival. Conclusion Our findings demonstrate that the adverse prognosis previously ascribed to DBD mutations in STAT1 GOF is predominantly driven by the T385M variant. Mutation-specific, rather than domain-level, stratification is therefore essential for accurate risk assessment and clinical management. In particular, patients predicted to have severe disease, such as those with the T385M mutation should be considered early for curative interventional therapies such as stem cell transplant or gene therapy.

Open article ↗



2025-11-28 | Table 3_The T385M STAT1 gain-of-function mutation confers the most severe disease outcomes.docx

Background Gain-of-function (GOF) mutations in STAT1 cause a combined immunodeficiency characterized by chronic mucocutaneous candidiasis (CMC), recurrent infections, and autoimmunity. Mutations in the DNA-binding domain (DBD) have previously been associated with poor outcomes, but the contributions of specific variants to clinical phenotype remain unexplored. Methods We performed a systematic literature review to identify patients with confirmed STAT1 GOF mutations, integrating new cases with a previously reported international cohort. Clinical and genetic data were analyzed at both domain and mutation level to define genotype-phenotype correlations. Results A total of 533 unique patients from 36 countries were identified, harboring 135 distinct mutations. As previously reported, DBD mutations were associated with increased risk of systemic infections, bronchiectasis, autoimmunity, and reduced survival. However, mutation-level stratification revealed that the T385M variant accounted for much of this effect. Compared with both other DBD mutations and mutations elsewhere in STAT1, T385M conferred significantly higher rates of infection, bronchiectasis, autoimmunity, and premature death (p < 0.001). Conversely, certain coiled-coil (CC) domain mutations, such as R274Q, were associated with milder disease and improved survival. Conclusion Our findings demonstrate that the adverse prognosis previously ascribed to DBD mutations in STAT1 GOF is predominantly driven by the T385M variant. Mutation-specific, rather than domain-level, stratification is therefore essential for accurate risk assessment and clinical management. In particular, patients predicted to have severe disease, such as those with the T385M mutation should be considered early for curative interventional therapies such as stem cell transplant or gene therapy.

Open article ↗



2024-09-11 | The Outcome of Haematopoietic Stem Cell Transplantation in a Patient with STAT1 Gain-of-Function: A Case Report.

ABSTRACT Background: The human signal transducer and activator of transcription 1 (STAT1) is a latent cytoplasmic transcription factor and one of seven members of the STAT family. Autosomal dominant (AD) STAT1 gain-of-function (GOF), characterized by enhanced phosphorylation of the tyrosine-701 residue and STAT1 activation, is commonly associated with chronic mucocutaneous candidiasis (CMCC), immunodeficiency, aneurysms, malignancies, and autoimmune phenomena. The best management strategies for patients with STAT1 GOF remain unclear. Typically, the standard care includes supportive treatments such as antimicrobial prophylaxis, either alone or combined with immunoglobulin replacement therapy. Biological therapies such as JAK inhibitors have been shown to alleviate symptoms of infection and autoimmune disorders in patients with STAT1 GOF mutations. However, there is a lack of long-term outcome data for JAK inhibition. Hematopoietic stem cell transplantation (HSCT) is an alternative treatment option for a subset who experience a persistent disease course despite conventional therapy. However, the effectiveness of HSCT for this condition is not yet well established. Methods: Our patient’s medical records were analyzed retrospectively, including her medical history. Results: We present the outcome of HSCT performed on a 27-year-old female with STAT1 GOF, conducted as a treatment for acute myeloid leukemia (AML). Conclusion: HSCT may serve as an alternative and potentially curative treatment for certain STAT1 GOF patients with progressive, life-threatening conditions that do not respond to conventional therapies. Additional research is needed to improve the management of these patients. Statement of Novelty: We present a novel case study of HSCT as a treatment for AML in a 27-year-old patient with STAT1 GOF, highlighting the potential for curative outcomes in progressive, life-threatening conditions unresponsive to conventional therapies. This case contributes to the limited body of evidence supporting the efficacy and challenges of HSCT in STAT1 GOF patients.

Open article ↗



2023-05-16 | Pro & Postbiotics play a role in disruptive relationships between yeast and bacterias

Antimicrobial resistance is an inevitable evolutionary event. Pathogenic strains of Candida spp. have been increasing in a number of cases, so candidiasis has become a serious public health problem. Alternative therapeutic approaches are gaining "space" and attention in the treatment of fungal diseases. This study is a systematic review, using the identification, selection, inclusion, and exclusion criteria of the PRISMA method. Works were selected and separated in 5 tables. The Lactobacillus spp. causing opposite effects against several pathogenic microorganisms, being considered one of the probiotic that play essential functions of immunomodulation in the intestinal mucosa, with beneficial effects, restores and promotes the maintenance of vaginal microbiota. It is clear from the data investigated that the use of Lactobacillus may be an alternative therapeutic approach for the treatment or control of the spread of Candida species responsible for candidiasis.

Open article ↗



2022-04-01 | Generation and Characterization of iPS Cells Derived from APECED Patients for Gene Correction

APECED (Autoimmune-Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy) is a severe and incurable multiorgan autoimmune disease caused by mutations in the AIRE (autoimmune regulator) gene. Without functional AIRE, the development of central and peripheral immune tolerance is severely impaired allowing the accumulation of autoreactive immune cells in the periphery. This leads to multiple endocrine and non-endocrine autoimmune disorders and mucocutaneous candidiasis in APECED patients. Recent studies have suggested that AIRE also has novel functions in stem cells and contributes to the regulatory network of pluripotency. In preparation of therapeutic gene correction, we generated and assessed patient blood cell-derived iPSCs, potentially suitable for cell therapy in APECED. Here, we describe APECED-patient derived iPSCs's properties, expression of AIRE as well as classical stem cell markers by qPCR and immunocytochemistry. We further generated self-aggregated EBs of the iPSCs. We show that APECED patient-derived iPSCs and EBs do not have any major proliferative or apoptotic defects and that they express all the classical pluripotency markers similarly to healthy person iPSCs. The results suggest that the common AIRE R257X truncation mutation does not affect stem cell properties and that APECED iPSCs can be propagated in vitro and used for subsequent gene-correction. This first study on APECED patient-derived iPSCs validates their pluripotency and confirms their ability for differentiation and potential therapeutic use.

Open article ↗



proteins
2026-08-01 | EP245 - ECE_2602 - Teriparatide as an effective treatment for refractory hypocalcemia in Autoimmune Polyglandular Syndrome Type 1

Abstract Introduction Autoimmune Polyglandular Syndrome Type 1 (APS-1) is a rare inherited disorder characterized by the triad of chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency. Management of hypocalcemia in APS-1 can be challenging, particularly when malabsorption limits oral calcium and active vitamin D efficacy. Teriparatide, a recombinant PTH (1-34) analog, is not approved for hypoparathyroidism but has been used off-label in selected refractory cases. Case report Female, 26-year-old, followed in the Endocrinology Department since age 18 for APS-1, comprising primary adrenal insufficiency, primary hypoparathyroidism, premature ovarian insufficiency, autoimmune hepatitis, ectodermal dystrophy of dental enamel and nails, and exocrine pancreatic insufficiency. She was on calcium, calcitriol, azathioprine, hydrocortisone, fludrocortisone, estradiol, progesterone, and pancreatin. Since 2017, she has experienced recurrent episodes of symptomatic hypocalcemia despite high-dose calcitriol (2,25 µg/day) and calcium carbonate (4500 mg/day), typically triggered by diarrheal exacerbations. She reported a long-standing history of alternating diarrhea and constipation. In 2024, she presented to the Emergency Room with facial and extremities paresthesias and muscle stiffness. One month earlier, she started complaining of nausea, vomiting, and diarrhea, and the subsequent symptomatic hypocalcemia was treated with intravenous calcium gluconate(IV calcium) and increased oral calcium dose. At readmission, biochemical evaluation revealed hypokalemia, hypocalcemia, hypomagnesemia and normal serum phosphorus, and she started IV calcium and electrolyte correction. During the first 15 days of hospitalization, repeated attempts to discontinue IV calcium and maintain oral therapy alone resulted in recurrent severe hypocalcemia. On day 16, teriparatide 20 µg once daily was initiated as an off-label treatment for refractory and severe hypocalcemia. Within two days, IV calcium supplementation was successfully discontinued, and the patient transitioned to oral therapy, with diarrhea resolution. Following discharge, oral calcium carbonate and calcitriol doses were progressively reduced. Ten months later, she remains clinically stable with normal calcium, phosphorus, and calciuria on calcium carbonate 3000 mg/day, calcitriol 1 µg/day, and teriparatide 20 µg every other day. Conclusions This case supports the use of teriparatide as a potential therapeutic option for refractory hypocalcemia due to hypoparathyroidism in APS-1, especially when malabsorption limits conventional therapy. It should be reserved for selected patients under close monitoring. However, the optimal treatment duration remains uncertain, as long-term safety data are still limited.

Open article ↗



2026-08-01 | EP231 - ECE_2233 - Autoimmune polyendocrine syndrome type 1 caused by a momozygous aire mutation: report of two siblings

Abstract Introduction APS-1 (Autoimmune Polyendocrine Syndrome type 1) or APECED (Autoimmune Polyendocrinopathy–Candidiasis–Ectodermal Dystrophy) is a rare disease caused by biallelic genetic changes in the AIRE gene. The three most common clinical manifestations are chronic mucocutaneous candidiasis, hypoparathyroidism, and primary adrenal insufficiency (Addison's disease). More than 126 different mutations in the AIRE gene have been described. There is no clear genotype–phenotype correlation. A wide variability in the spectrum and severity of clinical manifestations has been described even among carriers with the same AIRE genetic change, even among siblings. We present the cases of two siblings (an older sister, 20 years old, and a younger brother, 17 years old) with a homozygous loss-of-function mutation in the AIRE gene. Case presentation The older sister was initially diagnosed at 6.5 years old with hypoparathyroidism and at 8 years with primary adrenal insufficiency. At 11 years, she remained at Tanner stage I, and biochemical evaluation revealed primary hypogonadism. She developed onychomycosis at 12 years and was also diagnosed with hypothyroidism at 16 years. The younger brother developed onychomycosis before the age of 9. At 9 years old, he was diagnosed with hypoparathyroidism and Addison's disease. He was also diagnosed with hypothyroidism at 10 years old. At the latest biochemical evaluation, at 17 years old, his gonadotropin levels showed an increasing trend indicative of primary gonadal insufficiency. Genetic testing revealed a homozygous AIRE variant, c.892G > A (p.Glu298Lys) in both siblings, while their parents were found to be heterozygous carriers. Conclusions Despite the well-known poor genotype–phenotype correlation in patients carrying the same pathogenic AIRE variants, herein, we describe two siblings with the same homozygous AIRE mutation who exhibited similar clinical manifestations, albeit with disease onset at different ages. Moreover, in the older sister, a switch from conventional therapy to palopegteriparatide was initiated upon reaching adulthood because of poorly controlled hypoparathyroidism.

Open article ↗



2026-07-17 | Palopegteriparatide Treatment for Hypoparathyroidism in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy - a Case Series and Literature Update

Abstract Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), also known as autoimmune polyglandular syndrome type 1 (APS-1), is an autosomal recessive disorder of thymic T cell negative selection that results in autoimmune destruction of various endocrine and extra-endocrine tissues. The classic clinical triad of the syndrome includes hypoparathyroidism (hypoPT), chronic mucocutaneous candidiasis (CMC), and adrenal insufficiency, while involvement of thyroid, pancreas, gonads, and ectodermal tissues are also frequently observed. Historically, treatment for hypoPT, the most common endocrine manifestation of APECED, has posed a unique challenge. Conventional therapy with oral calcium and active vitamin D analogues is often complicated by the presence of malabsorption and esophageal disorders, which are prevalent in APECED patients. Moreover, supplementation with oral calcium and active vitamin D analogues without correction of the underlying parathyroid hormone (PTH) insufficiency can result in renal and other soft-tissue calcifications. Short-acting PTH therapies, which have been used off-label in the treatment of hypoPT, fail to mimic normal parathyroid physiology due to their brief half-lives and can result in fluctuations of serum calcium levels between hypocalcemia and hypercalcemia. Long-acting PTH analogues have recently been developed to more closely mimic physiologic PTH activity. One such agent, palopegteriparatide, a prodrug of PTH (1,34), has shown promise to be the first hormone replacement therapy for hypoPT. We report our experience in four patients with APECED-associated hypoPT who initiated treatment with palopegteriparatide and were followed over the subsequent 4-15 month period. We observed a robust calcemic response to treatment during this follow-up window with wide fluctuations in serum calcium during this period of dose titration. These early observations highlight the effectiveness of palopegteriparatide in patients with APECED, enabling the discontinuation of oral calcium and active vitamin D supplements. They also highlight the question of whether etiology-specific differences in responsiveness may influence dose requirements and calcemic stability.

Open article ↗



2026-01-01 | Refractory hypoparathyroidism in paediatric autoimmune polyglandular syndrome type 1: successful long-term use of teriparatide

Autoimmune polyglandular syndrome type 1 (APS-1) is a rare monogenic disorder caused by pathogenic variants in the autoimmune regulator (AIRE) gene.It typically manifests in childhood with at least two features of the classic triad: chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency.We present the case of an 11-year-old girl from a consanguineous family, with severe hypocalcaemia and chronic oral candidiasis.Despite high-dose calcium and calcitriol therapy, she experienced recurrent symptomatic hypocalcaemia requiring multiple hospitalisations.Genetic testing confirmed homozygosity for the pathogenic AIRE variant c.967_979del, establishing the diagnosis of APS-1.Due to poor biochemical control, teriparatide (parathyroid hormone, PTH ) was initiated at 20 µg twice daily, leading to rapid improvement in calcium-phosphate homeostasis, a 75% reduction in oral calcium requirements, and no further hospitalisations over a two-year period.The therapy was well tolerated with no adverse events.This is the first paediatric case reported in Colombia using recombinant PTH (1-34) for APS-1-related hypoparathyroidism, supporting its therapeutic role in refractory cases.

Open article ↗



2024-05-17 | Qualitative Immunoglobulin Deficiency Causes Bacterial Infections in Patients with STAT1 Gain-of-Function Mutations.

STAT1 is a transduction and transcriptional regulator that functions within the classical JAK/STAT pathway. In addition to chronic mucocutaneous candidiasis, bacterial infections are a common occurrence in patients with STAT1 gain-of-function (GOF) mutations. These patients often exhibit skewing of B cell subsets; however, the impact of STAT1-GOF mutations on B cell-mediated humoral immunity remains largely unexplored. It is also unclear whether these patients with IgG within normal range require regular intravenous immunoglobulin (IVIG) therapy. Eleven patients (harboring nine different STAT1-GOF mutations) were enrolled. Reporter assays and immunoblot analyses were performed to confirm STAT1 mutations. Flow cytometry, deep sequencing, ELISA, and ELISpot were conducted to assess the impact of STAT1-GOF on humoral immunity. All patients exhibited increased levels of phospho-STAT1 and total STAT1 protein, with two patients carrying novel mutations. In vitro assays showed that these two novel mutations were GOF mutations. Three patients with normal total IgG levels received regular IVIG infusions, resulting in effective control of bacterial infections. Four cases showed impaired affinity and specificity of pertussis toxin-specific antibodies, accompanied by reduced generation of class-switched memory B cells. Patients also had a disrupted immunoglobulin heavy chain (IGH) repertoire, coupled with a marked reduction in the somatic hypermutation frequency of switched Ig transcripts. STAT1-GOF mutations disrupt B cell compartments and skew IGH characteristics, resulting in impaired affinity and antigen-specificity of antibodies and recurrent bacterial infections. Regular IVIG therapy can control these infections in patients, even those with normal total IgG levels.

Open article ↗



small molecules
2026-09-23 | Mild Phenotype in Functionally Validated STAT1 Gain-of-Function Disease Due to a Novel DNA-Binding Variant.

Signal transducer and activator of transcription 1 (STAT1) gain-of-function (GOF) disease is associated with chronic mucocutaneous candidiasis, infections, autoimmunity, and immune dysregulation; however, mutation-level determinants of phenotypic variability remain incompletely defined. We aimed to describe the clinical, immunologic, and functional features of four patients with STAT1-GOF disease, including three related patients carrying a novel DNA-binding domain (DBD) variant associated with a mild phenotype. Clinical manifestations, immunologic findings, and immune deficiency and dysregulation activity scores were analysed. Whole-exome sequencing (WES) with Sanger confirmation was performed, and the functional activity of the novel p.Leu400Pro variant was assessed using a gamma-activated sequence luciferase reporter assay after interferon-γ stimulation. All patients presented with early-onset chronic mucocutaneous candidiasis. Three related patients carrying p.Leu400Pro showed a mild, stable clinical course without severe infections or multisystem autoimmunity during a median follow-up of 8 years and had low disease activity scores. Functional analysis demonstrated increased IFN-γ-induced transcriptional activity compared with wild-type STAT1, reaching levels comparable to the established R274Q GOF control under the experimental conditions used and supporting a GOF effect. In contrast, an unrelated patient with p.Glu353Lys developed severe multisystem autoimmunity, lymphoproliferation, and bronchiectasis with high disease activity scores. Ruxolitinib led to clinical improvement and was used as bridging therapy before haematopoietic stem cell transplantation (HSCT). These findings identify a novel, functionally validated DNA-binding domain STAT1-GOF variant associated with a mild phenotype, supporting mutation-level risk stratification and individualized management. Targeted Janus kinase inhibition may help stabilize severe disease before transplantation.

Open article ↗



2026-09-21 | Thirty years of fluconazole therapy selects an azole-resistant Candida albicans isolate with a pre-adapted physiological, metabolic and structural state

Abstract Azole resistance in Candida albicans is traditionally attributed to alterations in drug targets and efflux mechanisms; however, how long-term antifungal exposure reshapes fungal physiology remains incompletely understood. Here, we characterize a fluconazole-resistant C. albicans clinical isolate (PUJ256) recovered from a patient with chronic mucocutaneous candidiasis after more than 30 years of continuous fluconazole therapy. Compared with the reference strain SC5314, the resistant isolate exhibited a clear fitness trade-off, with reduced filamentation and increased membrane vulnerability under basal conditions, yet enhanced fitness in the presence of fluconazole. Integration of phenotypic analyses with label-free quantitative proteomics revealed extensive metabolic remodelling, including coordinated regulation of central carbon metabolism, ergosterol biosynthesis and redox homeostasis. Notably, mitochondrial membrane potential was preserved in the resistant isolate under fluconazole stress, whereas the susceptible strain exhibited mitochondrial depolarization together with activation of MAPK signalling pathways. In addition, the resistant isolate displayed reduced susceptibility to phagocytosis under antifungal exposure, consistent with an increased capacity for persistence in the context of ongoing treatment. Collectively, our findings indicate that long-term azole resistance in C. albicans PUJ256 is associated with a stable, pre-adapted physiological state characterized by metabolic reprogramming and mitochondrial resilience. The prolonged antifungal exposure of this isolate provides a valuable opportunity to explore adaptative strategies that extend beyond canonical mechanisms, pointing to mitochondrial function and metabolic plasticity as potential targets for therapeutic intervention. Graphical abstract.

Open article ↗



2026-08-22 | TRAF3IP2 (Act1/CIKS) variants: A domain to phenotype framework and therapeutic implications.

Interleukin-17 (IL-17) family cytokines drive protective mucocutaneous immunity and, when dysregulated, a broad spectrum of inflammatory and autoimmune disease; almost all IL-17 receptor signaling converges on a single cytoplasmic adaptor, TRAF3IP2 (Act1/CIKS). This 574-amino-acid protein and U-box E3 ubiquitin ligase couples the IL-17 receptor to NF-κB and mitogen-activated protein kinase activation and also integrates non-IL-17 inputs through TRAF6, TRAF2/TRAF5, and TRAF3. Human germline variation in TRAF3IP2 offers a natural dissection of this adaptor along its signaling modules. Common coding variants that weaken TRAF6 recruitment, mainly rs33980500 (p.Asp19Asn), increase susceptibility to psoriasis and psoriatic arthritis, whereas rare biallelic variants that abolish SEFIR-mediated IL-17 receptor coupling cause chronic mucocutaneous candidiasis; an intermediate SEFIR lesion produces discoid lupus erythematosus. Additional associations span systemic lupus erythematosus, inflammatory bowel disease, cardiovascular disease, and malignancy. Interpreting these alleles has been limited by the absence of a variant catalogue anchored to a single protein reference and by a +9-residue offset between the 574- and 565-amino-acid isoforms that has propagated numbering errors across the literature. Here we assemble a reference-aligned atlas of 17 functionally or clinically annotated TRAF3IP2 variants on the 574-amino-acid sequence (NP_671733.2) and map each to the signaling interaction it perturbs. The resulting domain-to-phenotype framework, advanced as hypothesis-generating rather than deterministic, organizes variant effects along the IL-17 signaling axis, distinguishing TRAF-recruitment perturbation from receptor-coupling failure, and identifies the adaptor surfaces whose selective pharmacologic disruption could attenuate IL-17-driven inflammation in cardiovascular and oncologic disease while sparing antifungal immunity.

Open article ↗



2026-08-01 | Human inherited RORγT deficiency encompasses genetic heterogeneity, T cell deficiency, and clinical homogeneity.

We previously reported inherited RORγT deficiency in seven patients from three ancestries (Chilean, Palestinian, Saudi Arabian) with mycobacterial disease and chronic mucocutaneous candidiasis (CMC). We report here five additional patients from different ancestries (Afghan, Indian, Iranian, Japanese, Sri Lankan), each homozygous for a new loss-of-function RORC variant. All but one patient - the exception receiving early prophylaxis - developed mycobacterial disease due to a near-complete depletion of innate-like adaptive T cells, including MAIT and iNKT cells, low counts of adaptive TH1* and CD8+ T cells, and impaired Mycobacterium-induced IFN-γ production by the remaining cells of these subsets, NK cells, conventional CD4+ T, Vδ1, and Vδ2 γδT cells. Most patients also displayed CMC due to their low counts of TH17 and TH1* cells. One patient died from disseminated Bacille Calmette-Guérin (BCG) vaccine infection, but, unexpectedly, all the other patients are still alive and clinically stable. RORγT is essential for protective immunity against mycobacteria and Candida in humans.

Open article ↗



2026-07-16 | Approach to the patient with APS-1/APECED.

Autoimmune polyendocrine syndrome type 1 (APS-1), also known as Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a monogenic disorder of impaired central immune tolerance classically inherited in an autosomal recessive manner and caused by biallelic deleterious variants in the autoimmune regulator (AIRE) gene, leading to chronic mucocutaneous candidiasis (CMC) and multiorgan autoimmunity. Although hypoparathyroidism and adrenal insufficiency are among the most common and clinically consequential manifestations, it is increasingly recognized that several non-endocrine features - including autoimmune enteritis, urticarial eruption (termed APECED rash), enamel hypoplasia, autoimmune pneumonitis, and autoimmune hepatitis - often precede classical endocrinopathies, contributing to delayed diagnosis. Endocrinologists are often among the first specialists to encounter these patients and play a central role in early recognition and longitudinal care. Here we present five cases that illustrate the expanding clinical spectrum of APS-1, novel genetic mechanisms, key diagnostic challenges, and emerging therapeutic approaches. These cases highlight the importance of applying expanded clinical criteria and recognizing the limitations of standard genetic testing, including the need to consider deep intronic and dominant-negative AIRE variants. Finally, evolving mechanistic insights have established APS-1 as an interferon-γ (IFN-γ)-driven disease, providing a rationale for emerging targeted immunomodulatory therapies such as Janus kinase (JAK) inhibition with ruxolitinib. Early diagnosis enables proactive surveillance and may allow timely initiation of disease-modifying treatment.

Open article ↗



antibodies
2025-02-06 | Deciphering the role of IL17RA in psoriasis and chronic mucocutaneous candidiasis: shared pathways and distinct manifestations.

Psoriasis and chronic mucocutaneous candidiasis (CMC), although distinct in their clinical manifestations, often coexist within specific patient cohorts. Despite this intriguing clinical observation, their genetic etiologies have been studied separately, neglecting the shared inflammatory mediator, interleukin 17A-F (IL17A-F). Consequently, the immunogenetic foundations underlying these conditions have remained enigmatic. In this study, we analyzed the case of a 5-year-old female born to consanguineous parents who presented with concomitant psoriasis and CMC phenotypes. Utilizing whole exome and transcriptomic sequencing, we meticulously investigated the genetic underpinnings and molecular pathways underlying these complex pathologies. RNA sequencing was performed on a skin biopsy to confirm transcriptomic profiles associated with these conditions. We identified a novel bi-allelic variant (NM_014339.6, c.1173C>G A) within the interleukin 17 receptor type A (IL17RA) gene, resulting in a premature stop codon (p. Tyr391Ter). Despite the truncation, our investigations revealed that this variant produces a fully functional IL17RA protein. This was evident from the presence of IL17RA in the patient's peripheral blood mononuclear cells (PBMCs) and the ability of the mutant IL17RA to dimerize with both wild-type protein and its partners IL17RC and IL17RD. Transcriptomic analysis of the skin biopsy showed a distinct psoriasis-associated signature intertwined with inflammatory pathways, including responses to fungal infections. This report unveils an unprecedented genetic link serving as a common denominator for psoriasis and CMC. The novel IL17RA variant highlights the pivotal role of this receptor in the shared inflammatory pathways underlying these conditions. Our findings bridge a critical knowledge gap and provide insights into the molecular mechanisms connecting these diseases. This discovery not only advances our understanding of their pathophysiology but also lays the groundwork for personalized therapeutic strategies, heralding a new era of precision medicine for patients with intertwined psoriasis and CMC.

Open article ↗



2024-02-09 | Promising immunotherapeutic targets for treating candidiasis

In the last twenty years, there has been a significant increase in invasive fungal infections, which has corresponded with the expanding population of individuals with compromised immune systems. As a result, the mortality rate linked to these infections remains unacceptably high. The currently available antifungal drugs, such as azoles, polyenes, and echinocandins, face limitations in terms of their diversity, the escalating resistance of fungi and the occurrence of significant adverse effects. Consequently, there is an urgent need to develop new antifungal medications. Vaccines and antibodies present a promising avenue for addressing fungal infections due to their targeted antifungal properties and ability to modulate the immune response. This review investigates the structure and function of cell wall proteins, secreted proteins, and functional proteins within C. albicans . Furthermore, it seeks to analyze the current advancements and challenges in macromolecular drugs to identify new targets for the effective management of candidiasis.

Open article ↗



2023-05-05 | CMTM4 as a new partner for IL-17 receptor: adding a piece in the puzzle of IL17-driven diseases

IL-17 has emerged as an important cytokine in protecting the host from mucosal infections, but also as a pathogenic determinant and therapeutic target in numerous autoimmune and inflammatory diseases (e.g. psoriasis, psoriatic arthritis and ankylosing spondylitis, inflammatory bowel disease and multiple sclerosis) [(1)](#ref-0001). The IL-17 family includes six members (IL-17A to IL-17F) that act through the IL-17 receptors [(1)](#ref-0001). The most studied IL-17A, as well as IL-17F, binds to IL-17RA and IL-17RC resulting in heterodimerization. Currently IL-17A, IL-17F, IL-17RA or IL-23, a cytokine produced by innate immune cells that promotes expansion of Th17 cell populations, are targetable by monoclonal antibodies (mAbs). These mAbs have been approved for the treatment of different autoimmune diseases, most notably psoriasis, where their efficacy has outperformed conventional non-steroidal anti-inflammatory and tumor necrosis factor (TNF) blocking drugs. However, clinical trials and real-life experience have shown an increase in fungal and bacterial upper respiratory tract infections in patients treated with mAbs that block IL-23/IL-17 signaling. Accordingly, single nucleotide polymorphisms in genes encoding IL-17A, IL-17RA, IL-17RC, IL-23, or NF-κB activator 1 (ACT1, an adapter protein downstream of the IL-17R) which abrogate cellular responsiveness to IL-17A, were associated with susceptibility to chronic mucocutaneous candidiasis (CMC), a persistent infection of the skin, nails, and/or mucous membranes with commensal Candida species [(2)](#ref-0002). So new effective targeted approaches in IL-17 signaling are desirable. Knizkova and colleagues identified a new adaptor molecule involved in the IL-17/IL-17R cascade [(3)](#ref-0003). Through murine and human cell models, the authors found that CMTM4 (CKLF Like MARVEL Transmembrane Domain Containing 4) constitutively bound to the subunit IL-17RC becoming integral part of the IL-17R signaling complex (IL-17RSC) upon IL-17A stimulation. CMTM4 promoted the surface expression of IL-17RC by regulating posttranslational modifications, especially IL-17RC glycosylation and trafficking to trans-Golgi up to plasma membrane. CMTM4 was required for the recruitment of adapter ACT1, for the activation of p38, JNK and transcription of genes encoding proinflammatory cytokines upon IL-17A stimulation (Figure 1A). Keratinocytes from the tail of Cmtm4−/− mice specifically express lower levels of IL-17RC respect to Cmtm4 mice (Figure 1B). In vivo , when imiquimod (IMQ) was applied on the ears or shaven backs of Cmtm4 mice, they developed less severe psoriatic lesions and lower local expression of IL-17A target genes compared to Cmtm4 mice (Figure 1C).

Open article ↗



2023-01-10 | Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: A single center experience.

Autosomal dominant hyper-IgE syndrome (AD-HIES) caused by dominant negative (DN) variants in the signal transducer and activator of transcription 3 gene (STAT3) is characterized by recurrent Staphylococcal abscesses, severe eczema, chronic mucocutaneous candidiasis (CMC), and non-immunological facial and skeletal features. To describe our experience with the diagnosis and treatment of adult patients with AD-HIES induced by DN-STAT3 variants. The medical records of adult patients (>18 years) treated at the Allergy and Clinical Immunology Clinic of Hadassah Medical Center, Jerusalem, Israel, were retrospectively analyzed. Immune and genetic workups were used to confirm diagnosis. Three adult patients (2 males; age 29-41 years) were diagnosed with DN-STAT3 variants. All patients had non-immunological features, including coarse faces and osteopenia. Serious bacterial infections were noted in all patients, including recurrent abscesses, recurrent pneumonia, and bronchiectasis. CMC and diffuse dermatophytosis were noted in two patients. Two patients had severe atopic dermatitis refractory to topical steroids and phototherapy. Immune workup revealed elevated IgE in three patients and eosinophilia in two patients. Whole exome sequencing revealed DN-STAT3 variants (c.1166C>T; p.Thr389Ile in two patients and c.1268G>A; p. Arg423Gln in one patient). Variants were located in DNA-binding domain (DBD) and did not hamper STAT3 phosphorylation Treatment included antimicrobial prophylaxis with trimethoprim/sulfamethoxazole (n=2) and amoxycillin-clavulanic acid (n=1), and anti-fungal treatment with fluconazole (n=2) and voriconazole (n=1). Two patients who had severe atopic dermatitis, were treated with dupilumab with complete resolution of their rash. No adverse responses were noted in the dupilumab-treated patients. Dupilumab can be used safely as a biotherapy for atopic dermatitis in these patients as it can effectively alleviate eczema-related symptoms. Immunologists and dermatologists treating AD-HIES adult patients should be aware of demodicosis as a possible manifestation. DN-STAT3 variants in DBD do not hamper STAT3 phosphorylation.

Open article ↗



2022-11-20 | Antifungal chemotherapies and immunotherapies for the future

Human fungal pathogens cause a broad plethora of infections, spanning cutaneous dermatophytoses to invasive infections in immunocompromised hosts. As eukaryotic pathogens are capable of morphotype switching, they present unique challenges both for drug development and the immunological response. Whilst current antifungal therapies are limited to the orally available triazoles, intravenous echonocandins and polyenes, and flucytosine and terbinafine, there has been recent significant progress in the antifungal armamentorium with ibrexafungerp, a novel orally available terpanoid that inhibits 1,3-beta-D-glucan-approved by Food and Drug Administration in 2021, and fosmanogepix, an orally available pro-drug of manogepix, which targets glycosylphosphatidylinositol-anchored protein maturation entering Phase 3 studies for candidaemia. A number of further candidates are in development. There has been significant use of existing immunotherapies such as recombinant interferon-γ and G-CSF for fungal disease in immunocompromised patients, and there are emerging opportunities for monoclonal antibodies targeting TH2 inflammation. Omalizumab, an anti-IgE monoclonal antibody in asthma, is now used routinely for the treatment of allergic bronchopulmonary aspergillosis, and further agents targeting IL-4 and IL-5 are being evaluated. In addition, T-cell CAR therapy is showing early promise for fungal disease. Thus, we are likely to see rapid advances to our approach to the management of fungal disease in the near future.

Open article ↗



other
2026-08-09 | Functional restoration of immune defects in STAT1 gain-of-function disease following stem cell gene editing.

Germline gain-of-function (GOF) mutations in the signal transducer and activator of transcription 1 (STAT1) gene cause a dominantly inherited inborn error of immunity (IEI) characterized by chronic mucocutaneous candidiasis, autoimmunity, severe opportunistic infections and an increased risk of malignancy. Allogeneic hematopoietic stem cell (HSC) transplantation (HSCT) is curative but is associated with increased risk of morbidity and mortality in STAT1 GOF patients compared to other IEI. To develop a curative, autologous alternative to HSCT, we evaluated gene editing strategies in STAT1 GOF model cell lines, primary T cells, and patient-derived HSCs. Universal and mutation-specific strategies using CRISPR/Cas-mediated homology-directed repair (HDR) were limited by low efficacy (<25%), poor viability, and a lack of allele-specificity. In contrast, adenine base editing corrected the recurrent and highly pathogenic p.T385M mutation with upwards of 90% efficiency in patient T cells and HSCs without significant unintended on- or off-target genomic aberrations. Gene editing functionally restored total STAT1 expression (p<0.0217), STAT1 phosphorylation (p<0.0056), interferon-stimulated gene expression (OAS1; p=0.0005) and improved IL-17 production (p<0.0001). Edited HSCs retained multilineage differentiation capacity and sustained engraftment with persistence of the corrected allele at 16 weeks in humanized immunodeficient mice. These data demonstrate efficient and precise correction of STAT1 GOF mutations by base editing, with maintenance of the correction through long-term engraftment in vivo. This represents the first application of gene editing to correct a dominant gain-of-function mutation causing immunodeficiency, with potential applicability to other genetic disorders associated with heterozygous and gain-of-function mutations.

Open article ↗



cell therapies
2025-11-28 | The T385M STAT1 gain-of-function mutation confers the most severe disease outcomes

Background Gain-of-function (GOF) mutations in STAT1 cause a combined immunodeficiency characterized by chronic mucocutaneous candidiasis (CMC), recurrent infections, and autoimmunity. Mutations in the DNA-binding domain (DBD) have previously been associated with poor outcomes, but the contributions of specific variants to clinical phenotype remain unexplored. Methods We performed a systematic literature review to identify patients with confirmed STAT1 GOF mutations, integrating new cases with a previously reported international cohort. Clinical and genetic data were analyzed at both domain and mutation level to define genotype-phenotype correlations. Results A total of 533 unique patients from 36 countries were identified, harboring 135 distinct mutations. As previously reported, DBD mutations were associated with increased risk of systemic infections, bronchiectasis, autoimmunity, and reduced survival. However, mutation-level stratification revealed that the T385M variant accounted for much of this effect. Compared with both other DBD mutations and mutations elsewhere in STAT1 , T385M conferred significantly higher rates of infection, bronchiectasis, autoimmunity, and premature death (p &lt; 0.001). Conversely, certain coiled-coil (CC) domain mutations, such as R274Q, were associated with milder disease and improved survival. Conclusion Our findings demonstrate that the adverse prognosis previously ascribed to DBD mutations in STAT1 GOF is predominantly driven by the T385M variant. Mutation-specific, rather than domain-level, stratification is therefore essential for accurate risk assessment and clinical management. In particular, patients predicted to have severe disease, such as those with the T385M mutation should be considered early for curative interventional therapies such as stem cell transplant or gene therapy.

Open article ↗



2025-11-28 | Table 3_The T385M STAT1 gain-of-function mutation confers the most severe disease outcomes.docx

Background Gain-of-function (GOF) mutations in STAT1 cause a combined immunodeficiency characterized by chronic mucocutaneous candidiasis (CMC), recurrent infections, and autoimmunity. Mutations in the DNA-binding domain (DBD) have previously been associated with poor outcomes, but the contributions of specific variants to clinical phenotype remain unexplored. Methods We performed a systematic literature review to identify patients with confirmed STAT1 GOF mutations, integrating new cases with a previously reported international cohort. Clinical and genetic data were analyzed at both domain and mutation level to define genotype-phenotype correlations. Results A total of 533 unique patients from 36 countries were identified, harboring 135 distinct mutations. As previously reported, DBD mutations were associated with increased risk of systemic infections, bronchiectasis, autoimmunity, and reduced survival. However, mutation-level stratification revealed that the T385M variant accounted for much of this effect. Compared with both other DBD mutations and mutations elsewhere in STAT1, T385M conferred significantly higher rates of infection, bronchiectasis, autoimmunity, and premature death (p < 0.001). Conversely, certain coiled-coil (CC) domain mutations, such as R274Q, were associated with milder disease and improved survival. Conclusion Our findings demonstrate that the adverse prognosis previously ascribed to DBD mutations in STAT1 GOF is predominantly driven by the T385M variant. Mutation-specific, rather than domain-level, stratification is therefore essential for accurate risk assessment and clinical management. In particular, patients predicted to have severe disease, such as those with the T385M mutation should be considered early for curative interventional therapies such as stem cell transplant or gene therapy.

Open article ↗



2024-09-11 | The Outcome of Haematopoietic Stem Cell Transplantation in a Patient with STAT1 Gain-of-Function: A Case Report.

ABSTRACT Background: The human signal transducer and activator of transcription 1 (STAT1) is a latent cytoplasmic transcription factor and one of seven members of the STAT family. Autosomal dominant (AD) STAT1 gain-of-function (GOF), characterized by enhanced phosphorylation of the tyrosine-701 residue and STAT1 activation, is commonly associated with chronic mucocutaneous candidiasis (CMCC), immunodeficiency, aneurysms, malignancies, and autoimmune phenomena. The best management strategies for patients with STAT1 GOF remain unclear. Typically, the standard care includes supportive treatments such as antimicrobial prophylaxis, either alone or combined with immunoglobulin replacement therapy. Biological therapies such as JAK inhibitors have been shown to alleviate symptoms of infection and autoimmune disorders in patients with STAT1 GOF mutations. However, there is a lack of long-term outcome data for JAK inhibition. Hematopoietic stem cell transplantation (HSCT) is an alternative treatment option for a subset who experience a persistent disease course despite conventional therapy. However, the effectiveness of HSCT for this condition is not yet well established. Methods: Our patient’s medical records were analyzed retrospectively, including her medical history. Results: We present the outcome of HSCT performed on a 27-year-old female with STAT1 GOF, conducted as a treatment for acute myeloid leukemia (AML). Conclusion: HSCT may serve as an alternative and potentially curative treatment for certain STAT1 GOF patients with progressive, life-threatening conditions that do not respond to conventional therapies. Additional research is needed to improve the management of these patients. Statement of Novelty: We present a novel case study of HSCT as a treatment for AML in a 27-year-old patient with STAT1 GOF, highlighting the potential for curative outcomes in progressive, life-threatening conditions unresponsive to conventional therapies. This case contributes to the limited body of evidence supporting the efficacy and challenges of HSCT in STAT1 GOF patients.

Open article ↗



2023-05-16 | Pro & Postbiotics play a role in disruptive relationships between yeast and bacterias

Antimicrobial resistance is an inevitable evolutionary event. Pathogenic strains of Candida spp. have been increasing in a number of cases, so candidiasis has become a serious public health problem. Alternative therapeutic approaches are gaining "space" and attention in the treatment of fungal diseases. This study is a systematic review, using the identification, selection, inclusion, and exclusion criteria of the PRISMA method. Works were selected and separated in 5 tables. The Lactobacillus spp. causing opposite effects against several pathogenic microorganisms, being considered one of the probiotic that play essential functions of immunomodulation in the intestinal mucosa, with beneficial effects, restores and promotes the maintenance of vaginal microbiota. It is clear from the data investigated that the use of Lactobacillus may be an alternative therapeutic approach for the treatment or control of the spread of Candida species responsible for candidiasis.

Open article ↗



2022-04-01 | Generation and Characterization of iPS Cells Derived from APECED Patients for Gene Correction

APECED (Autoimmune-Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy) is a severe and incurable multiorgan autoimmune disease caused by mutations in the AIRE (autoimmune regulator) gene. Without functional AIRE, the development of central and peripheral immune tolerance is severely impaired allowing the accumulation of autoreactive immune cells in the periphery. This leads to multiple endocrine and non-endocrine autoimmune disorders and mucocutaneous candidiasis in APECED patients. Recent studies have suggested that AIRE also has novel functions in stem cells and contributes to the regulatory network of pluripotency. In preparation of therapeutic gene correction, we generated and assessed patient blood cell-derived iPSCs, potentially suitable for cell therapy in APECED. Here, we describe APECED-patient derived iPSCs's properties, expression of AIRE as well as classical stem cell markers by qPCR and immunocytochemistry. We further generated self-aggregated EBs of the iPSCs. We show that APECED patient-derived iPSCs and EBs do not have any major proliferative or apoptotic defects and that they express all the classical pluripotency markers similarly to healthy person iPSCs. The results suggest that the common AIRE R257X truncation mutation does not affect stem cell properties and that APECED iPSCs can be propagated in vitro and used for subsequent gene-correction. This first study on APECED patient-derived iPSCs validates their pluripotency and confirms their ability for differentiation and potential therapeutic use.

Open article ↗



proteins
2026-08-01 | EP245 - ECE_2602 - Teriparatide as an effective treatment for refractory hypocalcemia in Autoimmune Polyglandular Syndrome Type 1

Abstract Introduction Autoimmune Polyglandular Syndrome Type 1 (APS-1) is a rare inherited disorder characterized by the triad of chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency. Management of hypocalcemia in APS-1 can be challenging, particularly when malabsorption limits oral calcium and active vitamin D efficacy. Teriparatide, a recombinant PTH (1-34) analog, is not approved for hypoparathyroidism but has been used off-label in selected refractory cases. Case report Female, 26-year-old, followed in the Endocrinology Department since age 18 for APS-1, comprising primary adrenal insufficiency, primary hypoparathyroidism, premature ovarian insufficiency, autoimmune hepatitis, ectodermal dystrophy of dental enamel and nails, and exocrine pancreatic insufficiency. She was on calcium, calcitriol, azathioprine, hydrocortisone, fludrocortisone, estradiol, progesterone, and pancreatin. Since 2017, she has experienced recurrent episodes of symptomatic hypocalcemia despite high-dose calcitriol (2,25 µg/day) and calcium carbonate (4500 mg/day), typically triggered by diarrheal exacerbations. She reported a long-standing history of alternating diarrhea and constipation. In 2024, she presented to the Emergency Room with facial and extremities paresthesias and muscle stiffness. One month earlier, she started complaining of nausea, vomiting, and diarrhea, and the subsequent symptomatic hypocalcemia was treated with intravenous calcium gluconate(IV calcium) and increased oral calcium dose. At readmission, biochemical evaluation revealed hypokalemia, hypocalcemia, hypomagnesemia and normal serum phosphorus, and she started IV calcium and electrolyte correction. During the first 15 days of hospitalization, repeated attempts to discontinue IV calcium and maintain oral therapy alone resulted in recurrent severe hypocalcemia. On day 16, teriparatide 20 µg once daily was initiated as an off-label treatment for refractory and severe hypocalcemia. Within two days, IV calcium supplementation was successfully discontinued, and the patient transitioned to oral therapy, with diarrhea resolution. Following discharge, oral calcium carbonate and calcitriol doses were progressively reduced. Ten months later, she remains clinically stable with normal calcium, phosphorus, and calciuria on calcium carbonate 3000 mg/day, calcitriol 1 µg/day, and teriparatide 20 µg every other day. Conclusions This case supports the use of teriparatide as a potential therapeutic option for refractory hypocalcemia due to hypoparathyroidism in APS-1, especially when malabsorption limits conventional therapy. It should be reserved for selected patients under close monitoring. However, the optimal treatment duration remains uncertain, as long-term safety data are still limited.

Open article ↗



2026-08-01 | EP231 - ECE_2233 - Autoimmune polyendocrine syndrome type 1 caused by a momozygous aire mutation: report of two siblings

Abstract Introduction APS-1 (Autoimmune Polyendocrine Syndrome type 1) or APECED (Autoimmune Polyendocrinopathy–Candidiasis–Ectodermal Dystrophy) is a rare disease caused by biallelic genetic changes in the AIRE gene. The three most common clinical manifestations are chronic mucocutaneous candidiasis, hypoparathyroidism, and primary adrenal insufficiency (Addison's disease). More than 126 different mutations in the AIRE gene have been described. There is no clear genotype–phenotype correlation. A wide variability in the spectrum and severity of clinical manifestations has been described even among carriers with the same AIRE genetic change, even among siblings. We present the cases of two siblings (an older sister, 20 years old, and a younger brother, 17 years old) with a homozygous loss-of-function mutation in the AIRE gene. Case presentation The older sister was initially diagnosed at 6.5 years old with hypoparathyroidism and at 8 years with primary adrenal insufficiency. At 11 years, she remained at Tanner stage I, and biochemical evaluation revealed primary hypogonadism. She developed onychomycosis at 12 years and was also diagnosed with hypothyroidism at 16 years. The younger brother developed onychomycosis before the age of 9. At 9 years old, he was diagnosed with hypoparathyroidism and Addison's disease. He was also diagnosed with hypothyroidism at 10 years old. At the latest biochemical evaluation, at 17 years old, his gonadotropin levels showed an increasing trend indicative of primary gonadal insufficiency. Genetic testing revealed a homozygous AIRE variant, c.892G > A (p.Glu298Lys) in both siblings, while their parents were found to be heterozygous carriers. Conclusions Despite the well-known poor genotype–phenotype correlation in patients carrying the same pathogenic AIRE variants, herein, we describe two siblings with the same homozygous AIRE mutation who exhibited similar clinical manifestations, albeit with disease onset at different ages. Moreover, in the older sister, a switch from conventional therapy to palopegteriparatide was initiated upon reaching adulthood because of poorly controlled hypoparathyroidism.

Open article ↗



2026-07-17 | Palopegteriparatide Treatment for Hypoparathyroidism in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy - a Case Series and Literature Update

Abstract Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), also known as autoimmune polyglandular syndrome type 1 (APS-1), is an autosomal recessive disorder of thymic T cell negative selection that results in autoimmune destruction of various endocrine and extra-endocrine tissues. The classic clinical triad of the syndrome includes hypoparathyroidism (hypoPT), chronic mucocutaneous candidiasis (CMC), and adrenal insufficiency, while involvement of thyroid, pancreas, gonads, and ectodermal tissues are also frequently observed. Historically, treatment for hypoPT, the most common endocrine manifestation of APECED, has posed a unique challenge. Conventional therapy with oral calcium and active vitamin D analogues is often complicated by the presence of malabsorption and esophageal disorders, which are prevalent in APECED patients. Moreover, supplementation with oral calcium and active vitamin D analogues without correction of the underlying parathyroid hormone (PTH) insufficiency can result in renal and other soft-tissue calcifications. Short-acting PTH therapies, which have been used off-label in the treatment of hypoPT, fail to mimic normal parathyroid physiology due to their brief half-lives and can result in fluctuations of serum calcium levels between hypocalcemia and hypercalcemia. Long-acting PTH analogues have recently been developed to more closely mimic physiologic PTH activity. One such agent, palopegteriparatide, a prodrug of PTH (1,34), has shown promise to be the first hormone replacement therapy for hypoPT. We report our experience in four patients with APECED-associated hypoPT who initiated treatment with palopegteriparatide and were followed over the subsequent 4-15 month period. We observed a robust calcemic response to treatment during this follow-up window with wide fluctuations in serum calcium during this period of dose titration. These early observations highlight the effectiveness of palopegteriparatide in patients with APECED, enabling the discontinuation of oral calcium and active vitamin D supplements. They also highlight the question of whether etiology-specific differences in responsiveness may influence dose requirements and calcemic stability.

Open article ↗



2026-01-01 | Refractory hypoparathyroidism in paediatric autoimmune polyglandular syndrome type 1: successful long-term use of teriparatide

Autoimmune polyglandular syndrome type 1 (APS-1) is a rare monogenic disorder caused by pathogenic variants in the autoimmune regulator (AIRE) gene.It typically manifests in childhood with at least two features of the classic triad: chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency.We present the case of an 11-year-old girl from a consanguineous family, with severe hypocalcaemia and chronic oral candidiasis.Despite high-dose calcium and calcitriol therapy, she experienced recurrent symptomatic hypocalcaemia requiring multiple hospitalisations.Genetic testing confirmed homozygosity for the pathogenic AIRE variant c.967_979del, establishing the diagnosis of APS-1.Due to poor biochemical control, teriparatide (parathyroid hormone, PTH ) was initiated at 20 µg twice daily, leading to rapid improvement in calcium-phosphate homeostasis, a 75% reduction in oral calcium requirements, and no further hospitalisations over a two-year period.The therapy was well tolerated with no adverse events.This is the first paediatric case reported in Colombia using recombinant PTH (1-34) for APS-1-related hypoparathyroidism, supporting its therapeutic role in refractory cases.

Open article ↗



2024-05-17 | Qualitative Immunoglobulin Deficiency Causes Bacterial Infections in Patients with STAT1 Gain-of-Function Mutations.

STAT1 is a transduction and transcriptional regulator that functions within the classical JAK/STAT pathway. In addition to chronic mucocutaneous candidiasis, bacterial infections are a common occurrence in patients with STAT1 gain-of-function (GOF) mutations. These patients often exhibit skewing of B cell subsets; however, the impact of STAT1-GOF mutations on B cell-mediated humoral immunity remains largely unexplored. It is also unclear whether these patients with IgG within normal range require regular intravenous immunoglobulin (IVIG) therapy. Eleven patients (harboring nine different STAT1-GOF mutations) were enrolled. Reporter assays and immunoblot analyses were performed to confirm STAT1 mutations. Flow cytometry, deep sequencing, ELISA, and ELISpot were conducted to assess the impact of STAT1-GOF on humoral immunity. All patients exhibited increased levels of phospho-STAT1 and total STAT1 protein, with two patients carrying novel mutations. In vitro assays showed that these two novel mutations were GOF mutations. Three patients with normal total IgG levels received regular IVIG infusions, resulting in effective control of bacterial infections. Four cases showed impaired affinity and specificity of pertussis toxin-specific antibodies, accompanied by reduced generation of class-switched memory B cells. Patients also had a disrupted immunoglobulin heavy chain (IGH) repertoire, coupled with a marked reduction in the somatic hypermutation frequency of switched Ig transcripts. STAT1-GOF mutations disrupt B cell compartments and skew IGH characteristics, resulting in impaired affinity and antigen-specificity of antibodies and recurrent bacterial infections. Regular IVIG therapy can control these infections in patients, even those with normal total IgG levels.

Open article ↗



small molecules
2026-09-23 | Mild Phenotype in Functionally Validated STAT1 Gain-of-Function Disease Due to a Novel DNA-Binding Variant.

Signal transducer and activator of transcription 1 (STAT1) gain-of-function (GOF) disease is associated with chronic mucocutaneous candidiasis, infections, autoimmunity, and immune dysregulation; however, mutation-level determinants of phenotypic variability remain incompletely defined. We aimed to describe the clinical, immunologic, and functional features of four patients with STAT1-GOF disease, including three related patients carrying a novel DNA-binding domain (DBD) variant associated with a mild phenotype. Clinical manifestations, immunologic findings, and immune deficiency and dysregulation activity scores were analysed. Whole-exome sequencing (WES) with Sanger confirmation was performed, and the functional activity of the novel p.Leu400Pro variant was assessed using a gamma-activated sequence luciferase reporter assay after interferon-γ stimulation. All patients presented with early-onset chronic mucocutaneous candidiasis. Three related patients carrying p.Leu400Pro showed a mild, stable clinical course without severe infections or multisystem autoimmunity during a median follow-up of 8 years and had low disease activity scores. Functional analysis demonstrated increased IFN-γ-induced transcriptional activity compared with wild-type STAT1, reaching levels comparable to the established R274Q GOF control under the experimental conditions used and supporting a GOF effect. In contrast, an unrelated patient with p.Glu353Lys developed severe multisystem autoimmunity, lymphoproliferation, and bronchiectasis with high disease activity scores. Ruxolitinib led to clinical improvement and was used as bridging therapy before haematopoietic stem cell transplantation (HSCT). These findings identify a novel, functionally validated DNA-binding domain STAT1-GOF variant associated with a mild phenotype, supporting mutation-level risk stratification and individualized management. Targeted Janus kinase inhibition may help stabilize severe disease before transplantation.

Open article ↗



2026-09-21 | Thirty years of fluconazole therapy selects an azole-resistant Candida albicans isolate with a pre-adapted physiological, metabolic and structural state

Abstract Azole resistance in Candida albicans is traditionally attributed to alterations in drug targets and efflux mechanisms; however, how long-term antifungal exposure reshapes fungal physiology remains incompletely understood. Here, we characterize a fluconazole-resistant C. albicans clinical isolate (PUJ256) recovered from a patient with chronic mucocutaneous candidiasis after more than 30 years of continuous fluconazole therapy. Compared with the reference strain SC5314, the resistant isolate exhibited a clear fitness trade-off, with reduced filamentation and increased membrane vulnerability under basal conditions, yet enhanced fitness in the presence of fluconazole. Integration of phenotypic analyses with label-free quantitative proteomics revealed extensive metabolic remodelling, including coordinated regulation of central carbon metabolism, ergosterol biosynthesis and redox homeostasis. Notably, mitochondrial membrane potential was preserved in the resistant isolate under fluconazole stress, whereas the susceptible strain exhibited mitochondrial depolarization together with activation of MAPK signalling pathways. In addition, the resistant isolate displayed reduced susceptibility to phagocytosis under antifungal exposure, consistent with an increased capacity for persistence in the context of ongoing treatment. Collectively, our findings indicate that long-term azole resistance in C. albicans PUJ256 is associated with a stable, pre-adapted physiological state characterized by metabolic reprogramming and mitochondrial resilience. The prolonged antifungal exposure of this isolate provides a valuable opportunity to explore adaptative strategies that extend beyond canonical mechanisms, pointing to mitochondrial function and metabolic plasticity as potential targets for therapeutic intervention. Graphical abstract.

Open article ↗



2026-08-22 | TRAF3IP2 (Act1/CIKS) variants: A domain to phenotype framework and therapeutic implications.

Interleukin-17 (IL-17) family cytokines drive protective mucocutaneous immunity and, when dysregulated, a broad spectrum of inflammatory and autoimmune disease; almost all IL-17 receptor signaling converges on a single cytoplasmic adaptor, TRAF3IP2 (Act1/CIKS). This 574-amino-acid protein and U-box E3 ubiquitin ligase couples the IL-17 receptor to NF-κB and mitogen-activated protein kinase activation and also integrates non-IL-17 inputs through TRAF6, TRAF2/TRAF5, and TRAF3. Human germline variation in TRAF3IP2 offers a natural dissection of this adaptor along its signaling modules. Common coding variants that weaken TRAF6 recruitment, mainly rs33980500 (p.Asp19Asn), increase susceptibility to psoriasis and psoriatic arthritis, whereas rare biallelic variants that abolish SEFIR-mediated IL-17 receptor coupling cause chronic mucocutaneous candidiasis; an intermediate SEFIR lesion produces discoid lupus erythematosus. Additional associations span systemic lupus erythematosus, inflammatory bowel disease, cardiovascular disease, and malignancy. Interpreting these alleles has been limited by the absence of a variant catalogue anchored to a single protein reference and by a +9-residue offset between the 574- and 565-amino-acid isoforms that has propagated numbering errors across the literature. Here we assemble a reference-aligned atlas of 17 functionally or clinically annotated TRAF3IP2 variants on the 574-amino-acid sequence (NP_671733.2) and map each to the signaling interaction it perturbs. The resulting domain-to-phenotype framework, advanced as hypothesis-generating rather than deterministic, organizes variant effects along the IL-17 signaling axis, distinguishing TRAF-recruitment perturbation from receptor-coupling failure, and identifies the adaptor surfaces whose selective pharmacologic disruption could attenuate IL-17-driven inflammation in cardiovascular and oncologic disease while sparing antifungal immunity.

Open article ↗



2026-08-01 | Human inherited RORγT deficiency encompasses genetic heterogeneity, T cell deficiency, and clinical homogeneity.

We previously reported inherited RORγT deficiency in seven patients from three ancestries (Chilean, Palestinian, Saudi Arabian) with mycobacterial disease and chronic mucocutaneous candidiasis (CMC). We report here five additional patients from different ancestries (Afghan, Indian, Iranian, Japanese, Sri Lankan), each homozygous for a new loss-of-function RORC variant. All but one patient - the exception receiving early prophylaxis - developed mycobacterial disease due to a near-complete depletion of innate-like adaptive T cells, including MAIT and iNKT cells, low counts of adaptive TH1* and CD8+ T cells, and impaired Mycobacterium-induced IFN-γ production by the remaining cells of these subsets, NK cells, conventional CD4+ T, Vδ1, and Vδ2 γδT cells. Most patients also displayed CMC due to their low counts of TH17 and TH1* cells. One patient died from disseminated Bacille Calmette-Guérin (BCG) vaccine infection, but, unexpectedly, all the other patients are still alive and clinically stable. RORγT is essential for protective immunity against mycobacteria and Candida in humans.

Open article ↗



2026-07-16 | Approach to the patient with APS-1/APECED.

Autoimmune polyendocrine syndrome type 1 (APS-1), also known as Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a monogenic disorder of impaired central immune tolerance classically inherited in an autosomal recessive manner and caused by biallelic deleterious variants in the autoimmune regulator (AIRE) gene, leading to chronic mucocutaneous candidiasis (CMC) and multiorgan autoimmunity. Although hypoparathyroidism and adrenal insufficiency are among the most common and clinically consequential manifestations, it is increasingly recognized that several non-endocrine features - including autoimmune enteritis, urticarial eruption (termed APECED rash), enamel hypoplasia, autoimmune pneumonitis, and autoimmune hepatitis - often precede classical endocrinopathies, contributing to delayed diagnosis. Endocrinologists are often among the first specialists to encounter these patients and play a central role in early recognition and longitudinal care. Here we present five cases that illustrate the expanding clinical spectrum of APS-1, novel genetic mechanisms, key diagnostic challenges, and emerging therapeutic approaches. These cases highlight the importance of applying expanded clinical criteria and recognizing the limitations of standard genetic testing, including the need to consider deep intronic and dominant-negative AIRE variants. Finally, evolving mechanistic insights have established APS-1 as an interferon-γ (IFN-γ)-driven disease, providing a rationale for emerging targeted immunomodulatory therapies such as Janus kinase (JAK) inhibition with ruxolitinib. Early diagnosis enables proactive surveillance and may allow timely initiation of disease-modifying treatment.

Open article ↗



antibodies
2025-02-06 | Deciphering the role of IL17RA in psoriasis and chronic mucocutaneous candidiasis: shared pathways and distinct manifestations.

Psoriasis and chronic mucocutaneous candidiasis (CMC), although distinct in their clinical manifestations, often coexist within specific patient cohorts. Despite this intriguing clinical observation, their genetic etiologies have been studied separately, neglecting the shared inflammatory mediator, interleukin 17A-F (IL17A-F). Consequently, the immunogenetic foundations underlying these conditions have remained enigmatic. In this study, we analyzed the case of a 5-year-old female born to consanguineous parents who presented with concomitant psoriasis and CMC phenotypes. Utilizing whole exome and transcriptomic sequencing, we meticulously investigated the genetic underpinnings and molecular pathways underlying these complex pathologies. RNA sequencing was performed on a skin biopsy to confirm transcriptomic profiles associated with these conditions. We identified a novel bi-allelic variant (NM_014339.6, c.1173C>G A) within the interleukin 17 receptor type A (IL17RA) gene, resulting in a premature stop codon (p. Tyr391Ter). Despite the truncation, our investigations revealed that this variant produces a fully functional IL17RA protein. This was evident from the presence of IL17RA in the patient's peripheral blood mononuclear cells (PBMCs) and the ability of the mutant IL17RA to dimerize with both wild-type protein and its partners IL17RC and IL17RD. Transcriptomic analysis of the skin biopsy showed a distinct psoriasis-associated signature intertwined with inflammatory pathways, including responses to fungal infections. This report unveils an unprecedented genetic link serving as a common denominator for psoriasis and CMC. The novel IL17RA variant highlights the pivotal role of this receptor in the shared inflammatory pathways underlying these conditions. Our findings bridge a critical knowledge gap and provide insights into the molecular mechanisms connecting these diseases. This discovery not only advances our understanding of their pathophysiology but also lays the groundwork for personalized therapeutic strategies, heralding a new era of precision medicine for patients with intertwined psoriasis and CMC.

Open article ↗



2024-02-09 | Promising immunotherapeutic targets for treating candidiasis

In the last twenty years, there has been a significant increase in invasive fungal infections, which has corresponded with the expanding population of individuals with compromised immune systems. As a result, the mortality rate linked to these infections remains unacceptably high. The currently available antifungal drugs, such as azoles, polyenes, and echinocandins, face limitations in terms of their diversity, the escalating resistance of fungi and the occurrence of significant adverse effects. Consequently, there is an urgent need to develop new antifungal medications. Vaccines and antibodies present a promising avenue for addressing fungal infections due to their targeted antifungal properties and ability to modulate the immune response. This review investigates the structure and function of cell wall proteins, secreted proteins, and functional proteins within C. albicans . Furthermore, it seeks to analyze the current advancements and challenges in macromolecular drugs to identify new targets for the effective management of candidiasis.

Open article ↗



2023-05-05 | CMTM4 as a new partner for IL-17 receptor: adding a piece in the puzzle of IL17-driven diseases

IL-17 has emerged as an important cytokine in protecting the host from mucosal infections, but also as a pathogenic determinant and therapeutic target in numerous autoimmune and inflammatory diseases (e.g. psoriasis, psoriatic arthritis and ankylosing spondylitis, inflammatory bowel disease and multiple sclerosis) [(1)](#ref-0001). The IL-17 family includes six members (IL-17A to IL-17F) that act through the IL-17 receptors [(1)](#ref-0001). The most studied IL-17A, as well as IL-17F, binds to IL-17RA and IL-17RC resulting in heterodimerization. Currently IL-17A, IL-17F, IL-17RA or IL-23, a cytokine produced by innate immune cells that promotes expansion of Th17 cell populations, are targetable by monoclonal antibodies (mAbs). These mAbs have been approved for the treatment of different autoimmune diseases, most notably psoriasis, where their efficacy has outperformed conventional non-steroidal anti-inflammatory and tumor necrosis factor (TNF) blocking drugs. However, clinical trials and real-life experience have shown an increase in fungal and bacterial upper respiratory tract infections in patients treated with mAbs that block IL-23/IL-17 signaling. Accordingly, single nucleotide polymorphisms in genes encoding IL-17A, IL-17RA, IL-17RC, IL-23, or NF-κB activator 1 (ACT1, an adapter protein downstream of the IL-17R) which abrogate cellular responsiveness to IL-17A, were associated with susceptibility to chronic mucocutaneous candidiasis (CMC), a persistent infection of the skin, nails, and/or mucous membranes with commensal Candida species [(2)](#ref-0002). So new effective targeted approaches in IL-17 signaling are desirable. Knizkova and colleagues identified a new adaptor molecule involved in the IL-17/IL-17R cascade [(3)](#ref-0003). Through murine and human cell models, the authors found that CMTM4 (CKLF Like MARVEL Transmembrane Domain Containing 4) constitutively bound to the subunit IL-17RC becoming integral part of the IL-17R signaling complex (IL-17RSC) upon IL-17A stimulation. CMTM4 promoted the surface expression of IL-17RC by regulating posttranslational modifications, especially IL-17RC glycosylation and trafficking to trans-Golgi up to plasma membrane. CMTM4 was required for the recruitment of adapter ACT1, for the activation of p38, JNK and transcription of genes encoding proinflammatory cytokines upon IL-17A stimulation (Figure 1A). Keratinocytes from the tail of Cmtm4−/− mice specifically express lower levels of IL-17RC respect to Cmtm4 mice (Figure 1B). In vivo , when imiquimod (IMQ) was applied on the ears or shaven backs of Cmtm4 mice, they developed less severe psoriatic lesions and lower local expression of IL-17A target genes compared to Cmtm4 mice (Figure 1C).

Open article ↗



2023-01-10 | Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: A single center experience.

Autosomal dominant hyper-IgE syndrome (AD-HIES) caused by dominant negative (DN) variants in the signal transducer and activator of transcription 3 gene (STAT3) is characterized by recurrent Staphylococcal abscesses, severe eczema, chronic mucocutaneous candidiasis (CMC), and non-immunological facial and skeletal features. To describe our experience with the diagnosis and treatment of adult patients with AD-HIES induced by DN-STAT3 variants. The medical records of adult patients (>18 years) treated at the Allergy and Clinical Immunology Clinic of Hadassah Medical Center, Jerusalem, Israel, were retrospectively analyzed. Immune and genetic workups were used to confirm diagnosis. Three adult patients (2 males; age 29-41 years) were diagnosed with DN-STAT3 variants. All patients had non-immunological features, including coarse faces and osteopenia. Serious bacterial infections were noted in all patients, including recurrent abscesses, recurrent pneumonia, and bronchiectasis. CMC and diffuse dermatophytosis were noted in two patients. Two patients had severe atopic dermatitis refractory to topical steroids and phototherapy. Immune workup revealed elevated IgE in three patients and eosinophilia in two patients. Whole exome sequencing revealed DN-STAT3 variants (c.1166C>T; p.Thr389Ile in two patients and c.1268G>A; p. Arg423Gln in one patient). Variants were located in DNA-binding domain (DBD) and did not hamper STAT3 phosphorylation Treatment included antimicrobial prophylaxis with trimethoprim/sulfamethoxazole (n=2) and amoxycillin-clavulanic acid (n=1), and anti-fungal treatment with fluconazole (n=2) and voriconazole (n=1). Two patients who had severe atopic dermatitis, were treated with dupilumab with complete resolution of their rash. No adverse responses were noted in the dupilumab-treated patients. Dupilumab can be used safely as a biotherapy for atopic dermatitis in these patients as it can effectively alleviate eczema-related symptoms. Immunologists and dermatologists treating AD-HIES adult patients should be aware of demodicosis as a possible manifestation. DN-STAT3 variants in DBD do not hamper STAT3 phosphorylation.

Open article ↗



2022-11-20 | Antifungal chemotherapies and immunotherapies for the future

Human fungal pathogens cause a broad plethora of infections, spanning cutaneous dermatophytoses to invasive infections in immunocompromised hosts. As eukaryotic pathogens are capable of morphotype switching, they present unique challenges both for drug development and the immunological response. Whilst current antifungal therapies are limited to the orally available triazoles, intravenous echonocandins and polyenes, and flucytosine and terbinafine, there has been recent significant progress in the antifungal armamentorium with ibrexafungerp, a novel orally available terpanoid that inhibits 1,3-beta-D-glucan-approved by Food and Drug Administration in 2021, and fosmanogepix, an orally available pro-drug of manogepix, which targets glycosylphosphatidylinositol-anchored protein maturation entering Phase 3 studies for candidaemia. A number of further candidates are in development. There has been significant use of existing immunotherapies such as recombinant interferon-γ and G-CSF for fungal disease in immunocompromised patients, and there are emerging opportunities for monoclonal antibodies targeting TH2 inflammation. Omalizumab, an anti-IgE monoclonal antibody in asthma, is now used routinely for the treatment of allergic bronchopulmonary aspergillosis, and further agents targeting IL-4 and IL-5 are being evaluated. In addition, T-cell CAR therapy is showing early promise for fungal disease. Thus, we are likely to see rapid advances to our approach to the management of fungal disease in the near future.

Open article ↗



other
2026-08-09 | Functional restoration of immune defects in STAT1 gain-of-function disease following stem cell gene editing.

Germline gain-of-function (GOF) mutations in the signal transducer and activator of transcription 1 (STAT1) gene cause a dominantly inherited inborn error of immunity (IEI) characterized by chronic mucocutaneous candidiasis, autoimmunity, severe opportunistic infections and an increased risk of malignancy. Allogeneic hematopoietic stem cell (HSC) transplantation (HSCT) is curative but is associated with increased risk of morbidity and mortality in STAT1 GOF patients compared to other IEI. To develop a curative, autologous alternative to HSCT, we evaluated gene editing strategies in STAT1 GOF model cell lines, primary T cells, and patient-derived HSCs. Universal and mutation-specific strategies using CRISPR/Cas-mediated homology-directed repair (HDR) were limited by low efficacy (<25%), poor viability, and a lack of allele-specificity. In contrast, adenine base editing corrected the recurrent and highly pathogenic p.T385M mutation with upwards of 90% efficiency in patient T cells and HSCs without significant unintended on- or off-target genomic aberrations. Gene editing functionally restored total STAT1 expression (p<0.0217), STAT1 phosphorylation (p<0.0056), interferon-stimulated gene expression (OAS1; p=0.0005) and improved IL-17 production (p<0.0001). Edited HSCs retained multilineage differentiation capacity and sustained engraftment with persistence of the corrected allele at 16 weeks in humanized immunodeficient mice. These data demonstrate efficient and precise correction of STAT1 GOF mutations by base editing, with maintenance of the correction through long-term engraftment in vivo. This represents the first application of gene editing to correct a dominant gain-of-function mutation causing immunodeficiency, with potential applicability to other genetic disorders associated with heterozygous and gain-of-function mutations.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.